This phase 2 trial tests a DNA vaccine called PVX4 in 138 women with HPV16-related high-grade cervical dysplasia (CIN2/3). The vaccine is given as a shot with a small electrical pulse to help it enter cells. The goal is to see if it can clear the virus and make abnormal cervical …
Phase 2 • Sponsor: PapiVax Biotech, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 12:29 UTC